Compare Novartis AG (NVS) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Texas Instruments Incorporated — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Texas Instruments Incorporated trades at $291.99 (market cap $258.53B). The key difference: Novartis AG and Texas Instruments Incorporated are close in size by market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | TXN | |
|---|---|---|
Market Cap | $290.25B | $258.53B |
Sector | Health | Technology |
52-Week High | $168.62 | $332.35 |
52-Week Low | $113.50 | $153.33 |
Enterprise Value | $330.27B | $267.48B |
Dividend Yield | 3.17% | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Texas Instruments (TXN) trades at $284.02, down 2.47% over 24 hours, with technical signals leaning bearish. The company reported mixed recent earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue and net income have shown volatility, with 2025 figures at $17.68B and $5.00B respectively. Analysts maintain a consensus Buy rating with a $313.05 price target, indicating potential upside. Recent CFO transition news and AI-driven demand in data centers are key developments.
Outlook remains cautiously optimistic given strong profitability margins and analyst support, but risks include elevated valuation multiples and competitive pressures in the semiconductor sector. The stock's current price near support at $281 suggests a critical level for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
